In the present study, we aimed to develop a single therapy for CRC using CAR-T cell delivery of a combined PD-1-TREM2 single-chain fragment variable (scFv) derived from anti-TREM2 and anti-PD-1 antibodies designed for specific localization at the tumor site. This evidence concerns the gene TREM2 and colorectal carcinoma.